Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.
Type:
Grant
Filed:
August 31, 1999
Date of Patent:
February 17, 2004
Assignees:
Inhibitex, Inc., The Provost Fellows and Scholars of The College of the Holy
and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University System
Inventors:
Joseph M. Patti, Timothy J. Foster, Magnus Hook
Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.
Type:
Grant
Filed:
November 25, 1998
Date of Patent:
January 20, 2004
Assignees:
Inhibitex, Inc., Bioresearch Ireland, The Texas A&M University System
Inventors:
Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins